Letter by Calabrò and Gragnano Regarding Article, “Dual Antiplatelet Therapy Continuation Beyond 1 Year After Drug-Eluting Stents: A Meta-Analysis of Randomized Trials”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
We have read with great interest the recent publication by Ferrante et al1 regarding dual antiplatelet therapy (DAPT) continuation beyond 1 year after drug-eluting stents implantation. The authors reported that (1) extended DAPT was associated with a reduction in the risk of myocardial infarction and an increase in the risk of major bleeding; (2) DAPT prolongation had no substantial effect on mortality, stent thrombosis, and stroke; (3) there is an unmet need in patients treated with drug-eluting stents to identify who may benefit most from prolonging DAPT beyond 1 year. This article adds relevant data on this controversial issue, underlying the absence of standardized approach defining optimal DAPT duration in clinical practice.
International guidelines2 recommend DAPT (with low-dose aspirin …